Skip to content

Acetazolamide does not alter endurance exercise performance at 3,500-m altitude.

PMID 31804890 (2020): altitude, hypoxia — VO₂max, Time-trial performance (study note for endurance athletes).

Last updated/Feb 23, 2026, 10:34 PM

Study note • PMID 31804890

Acetazolamide does not alter endurance exercise performance at 3,500-m altitude.

Journal of applied physiology (Bethesda, Md. : 1985)2020 • DOI 10.1152/japplphysiol.00655.2019
Evidence C67/100
Action 2: Consider

Worth trying if it fits your goal and context.

ELI5

In plain language

Acetazolamide (AZ) is a medication commonly used to prevent acute mountain sickness (AMS) during rapid ascent to high altitude. (randomized trial; participants).

The abstract doesn’t indicate a clear change in Time-trial performance under the tested conditions. Treat this as a signal, not a guarantee; confirm methods and context in the full paper.

Takeaways

What the abstract suggests

  • Study question: Acetazolamide (AZ) is a medication commonly used to prevent acute mountain sickness (AMS) during rapid ascent to high altitude.
  • The abstract doesn’t indicate a clear change in Time-trial performance under the tested conditions.
  • Population: participants.
  • Protocol cues (title/abstract): 500 mg/day • 2 h • 24 h • 12 h • 22 h • 5.0 min.

Protocol

Protocol (as reported)

  • Intervention/exposure: altitude, hypoxia (vs placebo).
  • Dose/time/duration cues in abstract/title: 500 mg/day • 2 h • 24 h • 12 h • 22 h • 5.0 min • 2.9 min • 500 m.
  • Outcomes: VO₂max, Time-trial performance.
  • Replication note: abstracts often omit adherence and timing; confirm details before changing training or supplementation.

Fit

Who it helps, and who should skip it

Who it helps

  • Athletes similar to the study population (participants) working on altitude.
  • Athletes who can measure VO₂max, Time-trial performance with a repeatable workout or time-trial effort.

Who should skip

  • If you have symptoms or conditions that make the intervention risky, get professional guidance.
  • If you’re near race day and can’t safely test, defer the experiment.

Methods

What the study actually did

  • Design: randomized trial (placebo-controlled).
  • Population: participants.
  • Comparator: placebo.
  • Outcomes measured: VO₂max, Time-trial performance.
  • Protocol cues mentioned: 500 mg/day • 2 h • 24 h • 12 h • 22 h • 5.0 min • 2.9 min • 500 m.
  • Source: PubMed PMID 31804890 (2020) — Journal of applied physiology (Bethesda, Md. : 1985).

Results excerpt

What the abstract reports

There was no difference in time to complete 2 miles between AZ and PL after 2 h (20.7 +/- 3.2 vs.

Note: excerpts are short; for full context, read the paper.

Limits

Limitations & bias

  • Abstract-only summaries can miss critical details (population, protocol, adherence, and context).
  • Single studies often don’t generalize to your event, history, and training load; treat results as a starting point.
  • If your context differs (elite vs recreational; cycling vs running), adjust expectations and be conservative.
  • This is performance information, not medical advice.

Coaching beta

Get a plan that adapts to your life.

Join the 26weeks.ai TestFlight beta for adaptive coaching, recovery-aware adjustments, and race-week reminders.

Keep going

Sources